Ranbaxy’s Nexium Generic Exclusivity: A Hit Or A Miss?
This article was originally published in PharmAsia News
Executive Summary
The FDA has blocked Ranbaxy’s exclusivity on Roche’s antiviral drug valganciclovir, but has kept its options open on Nexium, the popular heartburn drug. Experts believe Ranbaxy’s Nexium launch opportunity is in for a potential risk, but they are also hopeful that application may now be set for an exhaustive review and all may not be lost yet.